Lexicon Announces Telotristat Etiprate Data To Be Presented At European Cancer Congress

Lexicon Pharmaceuticals, Inc.

today announced that data from its pivotal TELESTAR Phase 3 clinical study of telotristat etiprate has been accepted as a late-breaking presentation at the European Cancer Congress, which will be held September 25–29 in Vienna, Austria. Telotristat etiprate, which has received Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration, is in development for the treatment of carcinoid syndrome in cancer patients whose symptoms are not adequately controlled with the current standard of care. The abstract, entitled "Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the Phase 3 TELESTAR clinical trial)," (37 LBA) will be presented in a proffered paper session on gastrointestinal malignancies on September 29 by primary investigator Dr. Matthew Kulke, associate professor of medicine at Harvard Medical School, and director, Program in Neuroendocrine Tumors and Carcinoid Syndrome, Dana-Farber Cancer Institute. Topline results from the TELESTAR study were announced by Lexicon on August 3, 2015.